Neurocrine Biosciences (NBIX) Change in Accured Expenses (2010 - 2026)

Neurocrine Biosciences' Change in Accured Expenses history runs 17 years deep, the most recent figure standing at -$14.3 million for Q1 2026.

• Quarterly Change in Accured Expenses fell 376.67% year-over-year to -$14.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $148.9 million (up 152.37% YoY) and the FY2025 annual result came in at $160.2 million, up 269.12% from the prior year.
• Change in Accured Expenses was -$14.3 million for Q1 2026 at Neurocrine Biosciences, down from $76.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $124.4 million in Q3 2023 and bottomed at -$98.3 million in Q4 2023.
• A 5-year average of $20.8 million and a median of $30.9 million in 2025 frame the typical range for Change in Accured Expenses.
• Annual changes were most pronounced in 2023 — Change in Accured Expenses surged 279.27% — and 2024, when it tumbled 467.28%.
• Neurocrine Biosciences' Change in Accured Expenses stood at $37.6 million in 2022, then plunged by 361.44% to -$98.3 million in 2023, then soared by 178.64% to $77.3 million in 2024, then slipped by 1.03% to $76.5 million in 2025, then tumbled by 118.69% to -$14.3 million in 2026.
• Business Quant data shows NBIX's Change in Accured Expenses at -$14.3 million in Q1 2026, $76.5 million in Q4 2025, and $55.8 million in Q3 2025.